Clinical trial
Early Feasibility Study of Medtronic 3830 Lead Implantation Via the Middle Cardiac Vein in Patients With Prior or Planned Tricuspid Valve Intervention: MCV 3830 EFS
NCT07805525 is registered in ClinicalTrials.gov with Minneapolis Heart Institute Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Early Feasibility Study of Medtronic 3830 Lead Implantation Via the Middle Cardiac Vein in Patients With Prior or Planned Tricuspid Valve Intervention: MCV 3830 EFS
- Lead sponsor
- Minneapolis Heart Institute Foundation
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- January 31, 2028
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiac conduction disorders requiring permanent pacing in patients with prior or planned tricuspid valve intervention